We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda's discovery portfolio.